Eli Lilly Chief Scientific Officer explains Zepbound’s weight loss advantage

Share

Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins ‘Fast Money’ to talk Zepbound’s recent trial results and what it means for Eli Lilly’s future growth.

Source link

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *